Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Mereo BioPharma Group plc - Sponsored ADR (MREO) had Return on Tangible Equity of -19.95% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-6.72M |
|
-- |
|
-- |
|
$8.77M |
|
$-8.77M |
|
$2.05M |
|
$-6.72M |
|
$-6.72M |
|
$-6.72M |
|
$-6.72M |
|
$-6.72M |
|
$-6.72M |
|
$-8.77M |
|
$-8.60M |
|
160.36M |
|
160.36M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$40.03M |
|
$0.09M |
|
$0.58M |
|
$40.61M |
|
$6.18M |
|
-- |
|
$0.38M |
|
$6.56M |
|
$34.05M |
|
$33.67M |
|
$34.05M |
|
159.62M |
|
| Cash Flow Statement Financials | |
$-4.31M |
|
$-0.30M |
|
-- |
|
$40.99M |
|
$36.22M |
|
$-4.77M |
|
$1.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.31M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.73% |
|
|
Return on Tangible Equity |
-19.95% |
-16.54% |
|
-19.73% |
|
$0.21 |
|
$-0.03 |
|
$-0.03 |
|